AnaptysBio (ANAB) Defended at Wedbush

June 21, 2019 1:31 PM EDT
Get Alerts ANAB Hot Sheet
Price: $22.98 -2%

Rating Summary:
    6 Buy, 7 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 8
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten reiterated an Outperform rating and $146.00 price target on AnaptysBio (NASDAQ: ANAB) saying weaknesses is 'overdone'.

  • Topline REGN3500 data still demonstrated statistically-significant and clinically-meaningful improvements over placebo
  • REGN3500 and etokimab are different molecules—it’s likely they have different clinical profiles, and best-in-class potential for etokimab may bear out.
  • The effects of multiple etokimab dosing hasn’t been reported yet

For an analyst ratings summary and ratings history on AnaptysBio click here. For more ratings news on AnaptysBio click here.

Shares of AnaptysBio closed at $67.02 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk